4//SEC Filing
Cohen Yuval 4
Accession 0001193125-25-251639
CIK 0001595097other
Filed
Oct 26, 8:00 PM ET
Accepted
Oct 27, 4:23 PM ET
Size
14.8 KB
Accession
0001193125-25-251639
Insider Transaction Report
Form 4
Cohen Yuval
DirectorChief Executive Officer
Transactions
- Exercise/Conversion
Stock options (right to buy)
2025-10-24−18,660→ 31,079 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (18,660 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2025-10-24$4.26/sh+18,660$79,492→ 156,847 total - Sale
Common Stock, par value $0.0001 per share
2025-10-27$17.14/sh−8,973$153,797→ 138,187 total - Exercise/Conversion
Stock options (right to buy)
2025-10-27−8,973→ 22,106 totalExercise: $4.26From: 2024-02-13Exp: 2033-02-13→ Common Stock (8,973 underlying) - Exercise/Conversion
Common Stock, par value $0.0001 per share
2025-10-27$4.26/sh+8,973$38,225→ 147,160 total - Sale
Common Stock, par value $0.0001 per share
2025-10-24$17.01/sh−18,660$317,407→ 138,187 total
Footnotes (5)
- [F1]This amount includes 123,561 unvested RSUs subject to each grant's vesting schedule as previously reported.
- [F2]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 14, 2025.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.79 to $17.38. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.31. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]The annual option award was made in accordance with the terms of the issuer's 2014 Equity Compensation Plan. 25% of the option vested on February 13, 2024, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on March 13, 2024.
Documents
Issuer
Corbus Pharmaceuticals Holdings, Inc.
CIK 0001595097
Entity typeother
Related Parties
1- filerCIK 0001626003
Filing Metadata
- Form type
- 4
- Filed
- Oct 26, 8:00 PM ET
- Accepted
- Oct 27, 4:23 PM ET
- Size
- 14.8 KB